Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment ...

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Results to be discussed in KOL event today at 10 a.m. ETBETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage ...

Geely Auto Selects Cerence xUI to Power its Next-Gen, LLM-Powered In-Car AI Experience

As user demand for AI-powered experiences accelerates, Cerence xUI helps automakers bring LLM-based interaction to their vehicles at speed. With xUI, automakers deliver a natural, intuitive experience ...